BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35948584)

  • 1. A cross-sectional study assessing the relationship between non-alcoholic fatty liver disease and periodontal disease.
    Sato S; Kamata Y; Kessoku T; Shimizu T; Kobayashi T; Kurihashi T; Takashiba S; Hatanaka K; Hamada N; Kodama T; Higurashi T; Taguri M; Yoneda M; Usuda H; Wada K; Nakajima A; Morozumi T; Minabe M
    Sci Rep; 2022 Aug; 12(1):13621. PubMed ID: 35948584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Imajo K; Honda Y; Kobayashi T; Nagai K; Ozaki A; Iwaki M; Kessoku T; Ogawa Y; Takahashi H; Saigusa Y; Yoneda M; Kirikoshi H; Utsunomiya D; Aishima S; Saito S; Nakajima A
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):908-917.e11. PubMed ID: 33340780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease.
    Yoneda M; Naka S; Nakano K; Wada K; Endo H; Mawatari H; Imajo K; Nomura R; Hokamura K; Ono M; Murata S; Tohnai I; Sumida Y; Shima T; Kuboniwa M; Umemura K; Kamisaki Y; Amano A; Okanoue T; Ooshima T; Nakajima A
    BMC Gastroenterol; 2012 Feb; 12():16. PubMed ID: 22340817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Singh S; Muir AJ; Dieterich DT; Falck-Ytter YT
    Gastroenterology; 2017 May; 152(6):1544-1577. PubMed ID: 28442120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Ajmera VH; Liu A; Singh S; Yachoa G; Ramey M; Bhargava M; Zamani A; Lopez S; Mangla N; Bettencourt R; Rizo E; Valasek M; Behling C; Richards L; Sirlin C; Loomba R
    Hepatology; 2020 Mar; 71(3):849-860. PubMed ID: 31556124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
    Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
    World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience.
    Fitriakusumah Y; Lesmana CRA; Bastian WP; Jasirwan COM; Hasan I; Simadibrata M; Kurniawan J; Sulaiman AS; Gani RA
    BMC Gastroenterol; 2019 Mar; 19(1):43. PubMed ID: 30894137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.
    Park JG; Jung J; Verma KK; Kang MK; Madamba E; Lopez S; Qas Yonan A; Liu A; Bettencourt R; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2021 May; 53(9):1030-1037. PubMed ID: 33764550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease.
    Lee YS; Yoo YJ; Jung YK; Kim JH; Seo YS; Yim HJ; Kim IH; Lee SY; Kim BH; Kim JW; Lee CH; Yeon JE; Kwon SY; Um SH; Byun KS
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00157. PubMed ID: 32251018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.